Johannes Brägelmann

4.4k total citations
39 papers, 1.0k citations indexed

About

Johannes Brägelmann is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Johannes Brägelmann has authored 39 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 15 papers in Pulmonary and Respiratory Medicine and 14 papers in Oncology. Recurrent topics in Johannes Brägelmann's work include Prostate Cancer Treatment and Research (6 papers), Lung Cancer Treatments and Mutations (5 papers) and Epigenetics and DNA Methylation (5 papers). Johannes Brägelmann is often cited by papers focused on Prostate Cancer Treatment and Research (6 papers), Lung Cancer Treatments and Mutations (5 papers) and Epigenetics and DNA Methylation (5 papers). Johannes Brägelmann collaborates with scholars based in Germany, United States and United Kingdom. Johannes Brägelmann's co-authors include Sven Perner, Mario C. Deng, Joachim L. Schultze, Nuno Saraiva-Agostinho, Andreas Schröck, Glen Kristiansen, Peter Brossart, Friedrich Bootz, Jutta Kirfel and Martin L. Sos and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Johannes Brägelmann

37 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Johannes Brägelmann Germany 16 557 352 313 296 122 39 1.0k
Gregor Sturm Austria 11 541 1.0× 421 1.2× 308 1.0× 308 1.0× 404 3.3× 23 1.1k
Jinning Ye China 15 327 0.6× 246 0.7× 323 1.0× 264 0.9× 106 0.9× 35 863
Daniel Brattström Sweden 17 365 0.7× 451 1.3× 401 1.3× 237 0.8× 54 0.4× 43 874
Long Bai China 15 342 0.6× 417 1.2× 240 0.8× 208 0.7× 40 0.3× 31 876
Habib Hamidi United States 16 685 1.2× 437 1.2× 335 1.1× 310 1.0× 96 0.8× 41 1.2k
E. Levchenko Russia 12 341 0.6× 510 1.4× 451 1.4× 178 0.6× 147 1.2× 75 908
Shunjun Fu China 17 360 0.6× 607 1.7× 174 0.6× 395 1.3× 221 1.8× 48 1.2k
Jean‐Christophe Sabourin France 15 492 0.9× 734 2.1× 420 1.3× 243 0.8× 230 1.9× 29 1.4k
Tomoyoshi Takayama Japan 16 401 0.7× 464 1.3× 462 1.5× 180 0.6× 142 1.2× 43 1.2k

Countries citing papers authored by Johannes Brägelmann

Since Specialization
Citations

This map shows the geographic impact of Johannes Brägelmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johannes Brägelmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johannes Brägelmann more than expected).

Fields of papers citing papers by Johannes Brägelmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johannes Brägelmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johannes Brägelmann. The network helps show where Johannes Brägelmann may publish in the future.

Co-authorship network of co-authors of Johannes Brägelmann

This figure shows the co-authorship network connecting the top 25 collaborators of Johannes Brägelmann. A scholar is included among the top collaborators of Johannes Brägelmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johannes Brägelmann. Johannes Brägelmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Scheel, Andreas H., Margaret Dugan, Robert Wild, et al.. (2024). Benchmark of screening markers for KEAP1/NFE2L2 mutations and joint analysis with the K1N2-score. npj Precision Oncology. 8(1). 259–259.
3.
Ahmad, Waleed, Andrey Bychkov, Junya Fukuoka, et al.. (2024). Next-generation lung cancer pathology: Development and validation of diagnostic and prognostic algorithms. Cell Reports Medicine. 5(9). 101697–101697. 8 indexed citations
4.
Brägelmann, Johannes, et al.. (2024). Unklare Minderung des Allgemeinzustandes bei Patientin mit Lungenkarzinom. Die Innere Medizin. 65(6). 612–616.
5.
Lorenz, Carina, Maria Cartolano, Dennis Plenker, et al.. (2023). Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer. Cancer Research. 83(15). 2471–2479. 7 indexed citations
6.
Dugan, Margaret, Robert Wild, Barbara Holz, et al.. (2023). KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC. Journal of Thoracic Oncology. 18(11). 1550–1567. 11 indexed citations
7.
Offermann, Anne, Lars Tharun, Jochen Behrends, et al.. (2022). Inhibition of Cyclin-Dependent Kinase 8/Cyclin-Dependent Kinase 19 Suppresses Its Pro-Oncogenic Effects in Prostate Cancer. American Journal Of Pathology. 192(5). 813–823. 7 indexed citations
8.
Müller, Fabienne, Jonathan Lim, Christina M. Bebber, et al.. (2022). Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation. Cell Death and Differentiation. 30(2). 442–456. 91 indexed citations
9.
Borchmann, Sven, Margarete Odenthal, Alexandra Florin, et al.. (2022). EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer. Cancers. 14(16). 3943–3943. 14 indexed citations
10.
Offermann, Anne, Marie C. Hupe, Johannes Brägelmann, et al.. (2021). CDK19 as a diagnostic marker for high-grade prostatic intraepithelial neoplasia. Human Pathology. 117. 60–67. 3 indexed citations
11.
Idel, Christian, Julika Ribbat‐Idel, Dirk Rades, et al.. (2020). CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC. International Journal of Molecular Sciences. 21(15). 5508–5508. 7 indexed citations
12.
Hupe, Marie C., Doris Roth, Rosemarie Krupar, et al.. (2019). Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer. International Journal of Cancer. 146(2). 577–588. 25 indexed citations
13.
Malchers, Florian, Meryem S. Ercanoglu, Roberta Castiglione, et al.. (2017). Mechanisms of Primary Drug Resistance in FGFR1 -Amplified Lung Cancer. Clinical Cancer Research. 23(18). 5527–5536. 41 indexed citations
14.
Müller, Tim, Martin Braun, Dimo Dietrich, et al.. (2017). PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma. Oncotarget. 8(32). 52889–52900. 93 indexed citations
15.
Mäßenhausen, Anne von, Johannes Brägelmann, Angela Queisser, et al.. (2016). Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression. International Journal of Molecular Sciences. 18(1). 7–7. 37 indexed citations
16.
Deng, Mario C., et al.. (2016). FirebrowseR: an R client to the Broad Institute’s Firehose Pipeline. Database. 2017. baw160–baw160. 113 indexed citations
17.
Pfister, Roman, Guido Michels, Johannes Brägelmann, et al.. (2014). Plasma vitamin C and risk of hospitalisation with diagnosis of atrial fibrillation in men and women in EPIC-Norfolk prospective study. International Journal of Cardiology. 177(3). 830–835. 14 indexed citations
18.
Khattri, Arun, Zhixiang Zuo, Johannes Brägelmann, et al.. (2014). Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma. Oral Oncology. 51(1). 53–58. 28 indexed citations
19.
Brägelmann, Johannes, Roman Pfister, & G. Michels. (2014). Stellenwert der Notfallechokardiographie am Beispiel einer akuten Aortendissektion. Medizinische Klinik - Intensivmedizin und Notfallmedizin. 109(5). 364–367. 2 indexed citations
20.
Brägelmann, Johannes, Ibiayi Dagogo‐Jack, Mohamed El Dinali, et al.. (2013). Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA. Oral Oncology. 49(6). 525–533. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gregor Sturm Breakdown of academic impact, for papers by Jinning Ye Breakdown of academic impact, for papers by Daniel Brattström Breakdown of academic impact, for papers by Long Bai Breakdown of academic impact, for papers by Habib Hamidi Breakdown of academic impact, for papers by E. Levchenko Breakdown of academic impact, for papers by Shunjun Fu Breakdown of academic impact, for papers by Jean‐Christophe Sabourin Breakdown of academic impact, for papers by Tomoyoshi Takayama
Rankless by CCL
2026